

**Amendments to the Specification:**

Please replace the table beginning on page 191, line 1 (Table 12), with the following amended table:

**Table 12: Comparative Antiviral Activity\* (EC<sub>50</sub>)**

	BVDV		YFV	
	EC <sub>50</sub> *	CC <sub>50</sub> **	EC <sub>50</sub> *	CC <sub>50</sub> **
β-D-2'-CH <sub>3</sub> -riboG	2	>100	1.2	20
β-D-2'-CH <sub>3</sub> -riboC	3.7	>100	70	>100
β-D-2'-CH <sub>3</sub> -riboU	20	>100	33	>100

\* Compound concentration (μM) required to reduce the plaque number by 50%. The following virus-cell system were used: BVDC-BT and YFV-BHK.

\*\* Compound concentration (μM) required to reduce the viability of cells by 50%.